Trials / Completed
CompletedNCT02608697
A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 153 (actual)
- Sponsor
- Catabasis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this placebo-controlled, double-blind study is to assess the effect of several doses of CAT-2054 on LDL-C in hypercholesterolemic patients on a stable dose of high-intensity statin, and to evaluate the safety and tolerability of different doses of CAT-2054 for 4 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CAT-2054 | |
| DRUG | Placebo | |
| DRUG | Atorvastatin |
Timeline
- Start date
- 2015-10-01
- Primary completion
- 2016-05-01
- Completion
- 2016-06-01
- First posted
- 2015-11-20
- Last updated
- 2017-06-20
Locations
34 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02608697. Inclusion in this directory is not an endorsement.